The shadow of generic rivalry has repeatedly loomed above copyright’s famous drug, PDE5 Inhibitor, sparking questions about the outlook of similar pharmaceutical portfolios. While initial years saw impressive returns, the patent lapse has opened the path for discounted copies, possibly reducing r